Literature DB >> 4616840

The chemical and biological properties of busulphan ("Myleran").

C D Dunn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4616840

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


× No keyword cloud information.
  13 in total

1.  JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Authors:  Emil T Kuriakose; Stefani Gjoni; Y Lynn Wang; Ruth Baumann; Amy V Jones; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

2.  Time-dependence and selectivity of immunosuppressive agents.

Authors:  M C Berenbaum
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

3.  Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.

Authors:  W E Beschorner; J Pino; J K Boitnott; P J Tutschka; G W Santos
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

Review 4.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

5.  Protective effect of testosterone or 5 beta-dihydrotestosterone pretreatment on CFU-E numbers in busulfan-treated rabbits.

Authors:  B Mödder; G Fütterer
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.

Authors:  Shuichi Ashizuka; William H Peranteau; Satoshi Hayashi; Alan W Flake
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

7.  Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity.

Authors:  S Sharma; V Kochupillai; H P Pati
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

8.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

Authors:  Edward A Copelan; Betty K Hamilton; Belinda Avalos; Kwang Woo Ahn; Brian J Bolwell; Xiaochun Zhu; Mahmoud Aljurf; Koen van Besien; Christopher Bredeson; Jean-Yves Cahn; Luciano J Costa; Marcos de Lima; Robert Peter Gale; Gregory A Hale; Joerg Halter; Mehdi Hamadani; Yoshihiro Inamoto; Rammurti T Kamble; Mark R Litzow; Alison W Loren; David I Marks; Eduardo Olavarria; Vivek Roy; Mitchell Sabloff; Bipin N Savani; Matthew Seftel; Harry C Schouten; Celalettin Ustun; Edmund K Waller; Daniel J Weisdorf; Baldeep Wirk; Mary M Horowitz; Mukta Arora; Jeff Szer; Jorge Cortes; Matt E Kalaycio; Richard T Maziarz; Wael Saber
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

9.  Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts.

Authors:  Matthew M Hsieh; Saskia Langemeijer; Aisha Wynter; Oswald A Phang; Elizabeth M Kang; John F Tisdale
Journal:  Exp Hematol       Date:  2007-07-09       Impact factor: 3.084

10.  Busulfan therapy of central nervous system xenografts in athymic mice.

Authors:  R H Aaron; G B Elion; O M Colvin; M Graham; S Keir; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.